| Quantity | 1 mg, 5 mg, 10 mg | 10 mM * 1 mL, 5 mg, 10 mg, 25 mg | 1 g, 5 g | 500 µ, g, 1 mg, 5 mg, 10 mg | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |
| Description | Ac-c[Cys-Glu-His-d-Phe-Arg-Trp-d-Cys]-Pro-Pro-Lys-Asp-NH2 (compound 5) is a selective hMC5R antagonist ligand with an IC50 of 10 nM[1] | DAMGO TFA is a µ-opioid receptor (µ-OPR ) selective agonist with a Kd of 3.46 nM for native µ-OPR[1] | NADase is a biochemical reagent that can be used as a biological material or organic compound for life science related research | PACAP (1-27), human, ovine, rat (PACAP 1-27) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor agonist with IC50s of 3 nM, 2 nM and 5 nM for rat PAC1, rat VPAC1 and human VPAC2, respectively[1] | Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake[1]... Read More |